From the category archives:

Papers

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis

by Nick on November 3, 2009

Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis

by Nick on November 1, 2009

Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis

by Nick on November 1, 2009

Development of a population-based microsimulation model of osteoarthritis in Canada

by Nick on October 23, 2009

The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis

by Nick on September 24, 2009

The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS

by Nick on September 1, 2009

Why do patients with inflammatory arthritis often score states “worse than death” on the EQ-5D? An Investigation of the EQ-5D classification system

by Nick on September 1, 2009

Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events

by Nick on August 15, 2009

Economic evaluation of systemic therapies for moderate to severe psoriasis

by Nick on June 1, 2009

Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis

by Nick on April 28, 2009

The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation

by Nick on April 1, 2009

Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis

by Nick on April 1, 2009

Obesity and overweight in Canada: an updated cost-of-illness study

by Nick on April 1, 2009

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis

by Nick on March 25, 2009

The economics of treatment in early rheumatoid arthritis

by Nick on February 1, 2009

Impact of the recall period on measuring health utilities for acute events

by Nick on December 28, 2008

Impact of the recall period on measuring health utilities for acute events

by Nick on December 1, 2008

Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States

by Nick on December 1, 2008

Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis

by Nick on September 1, 2008

Health state utility values: A description of their development and application for rheumatic diseases

by Nick on July 1, 2008

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration

by Nick on June 28, 2008

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration

by Nick on June 1, 2008

Biologic Drugs for Rheumatoid Arthritis in the Medicare Program

by Nick on April 1, 2008

The Validity and Responsiveness of Generic Utility Measures in Rheumatoid Arthritis: A Review

by Nick on April 1, 2008

Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

by Nick on February 1, 2008

Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration

by Nick on December 21, 2007

Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis

by Nick on August 15, 2007

Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

by Nick on August 1, 2007

The efficacy of inhibiting tumour necrosis factor {alpha} and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons

by Nick on July 1, 2007

Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis

by Nick on May 3, 2007

← Previous Entries